These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 38719949)

  • 1. A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance.
    Das C; Bhattacharya A; Adhikari S; Mondal A; Mondal P; Adhikary S; Roy S; Ramos K; Yadav KK; Tainer JA; Pandita TK
    Oncogene; 2024 Jun; 43(23):1727-1741. PubMed ID: 38719949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic-Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer.
    Das C; Adhikari S; Bhattacharya A; Chakraborty S; Mondal P; Yadav SS; Adhikary S; Hunt CR; Yadav KK; Pandita S; Roy S; Tainer JA; Ahmed Z; Pandita TK
    Cancer Res; 2023 Mar; 83(5):657-666. PubMed ID: 36661847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies.
    Trnkova L; Buocikova V; Mego M; Cumova A; Burikova M; Bohac M; Miklikova S; Cihova M; Smolkova B
    Biomed Pharmacother; 2024 May; 174():116559. PubMed ID: 38603889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
    Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
    Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer.
    Toska E
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189097. PubMed ID: 38518961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic mechanisms in breast cancer therapy and resistance.
    Garcia-Martinez L; Zhang Y; Nakata Y; Chan HL; Morey L
    Nat Commun; 2021 Mar; 12(1):1786. PubMed ID: 33741974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities.
    Ge T; Gu X; Jia R; Ge S; Chai P; Zhuang A; Fan X
    Cancer Commun (Lond); 2022 Nov; 42(11):1049-1082. PubMed ID: 36266736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
    Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
    Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
    Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
    Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance.
    Trimarchi MP; Mouangsavanh M; Huang TH
    Chin J Cancer; 2011 Nov; 30(11):749-56. PubMed ID: 22035855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.
    Greville G; McCann A; Rudd PM; Saldova R
    Epigenetics; 2016 Dec; 11(12):845-857. PubMed ID: 27689695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.
    Boulding T; McCuaig RD; Tan A; Hardy K; Wu F; Dunn J; Kalimutho M; Sutton CR; Forwood JK; Bert AG; Goodall GJ; Malik L; Yip D; Dahlstrom JE; Zafar A; Khanna KK; Rao S
    Sci Rep; 2018 Jan; 8(1):73. PubMed ID: 29311580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic and metabolic regulation of breast cancer stem cells.
    Liu HX; Li XL; Dong CF
    J Zhejiang Univ Sci B; 2015 Jan; 16(1):10-7. PubMed ID: 25559951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
    Perez-Plasencia C; Duenas-Gonzalez A
    Mol Cancer; 2006 Jul; 5():27. PubMed ID: 16831224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives.
    Sukocheva OA; Lukina E; Friedemann M; Menschikowski M; Hagelgans A; Aliev G
    Semin Cancer Biol; 2022 Jul; 82():35-59. PubMed ID: 33301860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response.
    Pathiraja TN; Stearns V; Oesterreich S
    J Mammary Gland Biol Neoplasia; 2010 Mar; 15(1):35-47. PubMed ID: 20101445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives of Reprogramming Breast Cancer Metabolism.
    Wang YP; Lei QY
    Adv Exp Med Biol; 2017; 1026():217-232. PubMed ID: 29282686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma.
    Lameirinhas A; Miranda-Gonçalves V; Henrique R; Jerónimo C
    Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30986931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells.
    Ponnusamy L; Mahalingaiah PKS; Chang YW; Singh KP
    Eur J Pharm Sci; 2018 Oct; 123():56-69. PubMed ID: 30016648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.